Stockscreener 앱 받기
111.43
1.85%
2.02
시간 외 거래:
111.01
-0.42
-0.38%
전일 마감가:
$109.41
열려 있는:
$108.87
하루 거래량:
620.24K
Relative Volume:
1.00
시가총액:
$6.80B
수익:
$3.84B
순이익/손실:
$330.79M
주가수익비율:
-70.97
EPS:
-1.57
순현금흐름:
$983.48M
1주 성능:
-0.43%
1개월 성능:
+1.87%
6개월 성능:
+1.29%
1년 성능:
-15.62%
1일 변동 폭
$108.73
$111.71
1주일 범위
$108.73
$113.58
52주 변동 폭
$99.06
$134.48
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Jazz Pharmaceuticals Iberia Recognized as One of the 100 Best Companies To Work for in Spain - CSRwire.com
Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics - Yahoo Finance
Private Advisor Group LLC Acquires 5,437 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Court Denies Jazz’s Challenge of Avadel’s Orphan Drug Lumryz - Sleep Review
US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle - Yahoo Finance
International Assets Investment Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia - StockTitan
Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ - Investing.com
Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation - Marketscreener.com
Jazz Pharma Loses Lawsuit Over FDA Approval of Rival Sleep Drug - Bloomberg Law
Court upholds FDA approval of Avadel's narcolepsy drug LUMRYZ By Investing.com - Investing.com UK
Avadel soars after court rules in favor of FDA in Lumryz case with Jazz Pharma - MSN
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation - The Manila Times
State of Alaska Department of Revenue Buys 26,370 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Set to Announce Earnings on Wednesday - MarketBeat
China Universal Asset Management Co. Ltd. Buys 4,472 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Drug Resistant Epilepsy Market Size, Industry Analysis, - openPR
With A 10% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock? - Yahoo Finance
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
Jazz Pharmaceuticals plc (JAZZ): Among the Best Stocks to Buy for High Returns in 2024 - Insider Monkey
Warther Private Wealth LLC Acquires Shares of 33,215 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals' SWOT analysis: stock outlook amid pipeline progress - Investing.com India
Jazz Pharmaceuticals' SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024 - Citizentribune
Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $179.00 - MarketBeat
Post Traumatic Stress Disorder Treatment Market Dynamic Growth - openPR
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet? - Simply Wall St
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Avadel wins FDA approval for narcolepsy drug Lumryz in children - Pharmaceutical Technology
Leerink Partnrs Has Pessimistic View of JAZZ FY2024 Earnings - MarketBeat
US FDA expands use of Avadel's sleep disorder drug to ages 7 and up - Reuters
Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a Bet - Yahoo Finance
Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now? - Yahoo Finance
Jazz Pharmaceuticals to terminate lease in 2025 - Investing.com
Is Jazz Pharmaceuticals plc (JAZZ) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey
JAZZ vs. ZTS: Which Stock Is the Better Value Option? - Yahoo Finance
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study - Zacks Investment Research
Is Jazz Pharmaceuticals (JAZZ) the Best Small-Cap Value Stock to Buy According to Hedge Funds? - Insider Monkey
Q4 2025 EPS Estimates for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Lifted by Analyst - MarketBeat
Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals’ Zepzelca combination meets endpoints in lung cancer trial - Yahoo Finance
Jazz Pharmaceuticals' lung cancer trial shows promise By Investing.com - Investing.com Canada
Jazz Pharma gains on late-stage trial win for cancer drug - MSN
Jazz Pharma stock gains on Zepzelca trial win (JAZZ:NASDAQ) - Seeking Alpha
Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Up 4.1%Still a Buy? - MarketBeat
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer - Yahoo Finance
PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer - Financial Times
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to Post Q2 2025 Earnings of $4.09 Per Share, Zacks Research Forecasts - MarketBeat
Jazz Pharmaceuticals' lung cancer trial shows promise - Investing.com
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):